{"filing":{"accession_number":"0001193125-26-303169","cik":"0001877184","ticker":"KMTS","company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","form":"8-K","filing_date":"2026-07-14","report_date":null,"primary_document":"ck0001877184-20260710.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1877184/000119312526303169/ck0001877184-20260710.htm"},"events":[{"id":17849,"run_id":16011,"accession_number":"0001193125-26-303169","anchor_item_number":"1.01","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.92,"summary":"Kestra Medical Technologies entered into a $200 million senior secured term loan facility on July 10, 2026, with $75 million funded immediately (Tranche A), replacing its prior loan agreement. The new facility has customary covenants, security interests in substantially all assets, and a five-year maturity, representing a material refinancing that fortified the company's balance sheet.","company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16469,"accession_number":"0001193125-26-303169","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Kestra entered into a $200 million senior secured term loan facility on July 10, 2026, with $75 million funded immediately (Tranche A). This is a material creation of direct financial obligations with customary covenants, security interests in substantially all assets, and a five-year maturity. The filing explicitly discloses this under Item 1.01 (Entry into a Material Definitive Agreement), and the debt issuance is a primary financing event for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:09:51.163716+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16470,"accession_number":"0001193125-26-303169","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Item 1.02 discloses termination of the Prior Loan Agreement with Perceptive Credit Holdings IV, LP and entry into a new Loan Agreement on July 10, 2026. While the Item title emphasizes termination, the substantive event is refinancing—replacement of one debt facility with another. The supplemental earnings release confirms \"fortification of our balance sheet\" and shows $262.2 million in cash and investments as of April 30, 2026, consistent with a refinancing that improved liquidity. This is classified as debt_issuance because the principal disclosed action is creation of a new direct financial obligation (the new Loan Agreement), even though it simultaneously terminated prior debt.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:09:51.163716+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":17850,"run_id":16011,"accession_number":"0001193125-26-303169","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Kestra Medical Technologies disclosed financial results for the fourth quarter and fiscal year ended April 30, 2026, reporting revenue of $95.1 million (59% year-over-year growth), gross margin expansion to 51.4%, and fiscal 2027 revenue guidance of $137 million. The disclosure includes consolidated financial statements and detailed financial highlights.","company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","filing_date":"2026-07-14","form":"8-K","submitted_at":null,"items":[{"id":16471,"accession_number":"0001193125-26-303169","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses Kestra Medical Technologies' financial results for the fourth quarter and fiscal year ended April 30, 2026, via a press release dated July 14, 2026. The disclosure includes detailed financial highlights (revenue of $95.1 million for FY26, up 59% YoY; gross margin expansion to 51.4%; FY27 revenue guidance of $137 million), consolidated statements of operations, balance sheets, and cash flow statements. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:09:51.163716+00:00","company_name":"","ticker":null,"filing_date":""},{"id":16472,"accession_number":"0001193125-26-303169","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Although Item 2.03 references Item 1.01 (a debt or financial obligation), the substantive disclosure in the supplemental exhibit (EX-99.1) is a comprehensive earnings release reporting fourth quarter and fiscal year 2026 financial results, including revenue of $95.1 million (59% growth), gross margin expansion to 51.4%, and FY27 guidance of $137 million. The earnings release is the material event being disclosed, not the debt obligation referenced in Item 2.03.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:09:51.163716+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16469,"accession_number":"0001193125-26-303169","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Kestra entered into a $200 million senior secured term loan facility on July 10, 2026, with $75 million funded immediately (Tranche A). This is a material creation of direct financial obligations with customary covenants, security interests in substantially all assets, and a five-year maturity. The filing explicitly discloses this under Item 1.01 (Entry into a Material Definitive Agreement), and the debt issuance is a primary financing event for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:09:51.163716+00:00","company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","filing_date":"2026-07-14"},{"id":16470,"accession_number":"0001193125-26-303169","item_number":"1.02","item_title":"Termination of a Material Definitive Agreement.","event_type":"debt_issuance","event_domain":"financial","is_material":true,"confidence":0.75,"reasoning":"Item 1.02 discloses termination of the Prior Loan Agreement with Perceptive Credit Holdings IV, LP and entry into a new Loan Agreement on July 10, 2026. While the Item title emphasizes termination, the substantive event is refinancing—replacement of one debt facility with another. The supplemental earnings release confirms \"fortification of our balance sheet\" and shows $262.2 million in cash and investments as of April 30, 2026, consistent with a refinancing that improved liquidity. This is classified as debt_issuance because the principal disclosed action is creation of a new direct financial obligation (the new Loan Agreement), even though it simultaneously terminated prior debt.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:09:51.163716+00:00","company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","filing_date":"2026-07-14"},{"id":16471,"accession_number":"0001193125-26-303169","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses Kestra Medical Technologies' financial results for the fourth quarter and fiscal year ended April 30, 2026, via a press release dated July 14, 2026. The disclosure includes detailed financial highlights (revenue of $95.1 million for FY26, up 59% YoY; gross margin expansion to 51.4%; FY27 revenue guidance of $137 million), consolidated statements of operations, balance sheets, and cash flow statements. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and trajectory.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:09:51.163716+00:00","company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","filing_date":"2026-07-14"},{"id":16472,"accession_number":"0001193125-26-303169","item_number":"2.03","item_title":"Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Although Item 2.03 references Item 1.01 (a debt or financial obligation), the substantive disclosure in the supplemental exhibit (EX-99.1) is a comprehensive earnings release reporting fourth quarter and fiscal year 2026 financial results, including revenue of $95.1 million (59% growth), gross margin expansion to 51.4%, and FY27 guidance of $137 million. The earnings release is the material event being disclosed, not the debt obligation referenced in Item 2.03.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-14T20:09:51.163716+00:00","company_name":"KESTRA MEDICAL TECHNOLOGIES, LTD.","ticker":"KMTS","filing_date":"2026-07-14"}]}